CD31 peptides
The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
1. A pharmaceutical composition comprising an isolated peptide consisting of:
(SEQ ID NO: 5)
(i) H-RVFLAPWK-OH,
(SEQ ID NO: 6)
(ii) H-kwpalfvr-OH,
(SEQ ID NO: 7)
(iii) H-RVILAPWK-OH,
(SEQ ID NO: 8)
(iv) H-kwpalivr-OH,
or
(v) a chemically modified peptide of (i), (ii), (iii), or (iv) which has at least one chemical modification selected from the group consisting of:
modification to the N-terminal and/or C-terminal end of the peptide by N-terminal acylation or deamination;
modification of the C-terminal carboxyl group into an amide or an alcohol group;
modification at the amide bond between two amino acids by acylation or alkylation at the nitrogen atom or the alpha carbon of the amide bond linking two amino acids;
modification at the alpha carbon of the amide bond linking two amino acids by acylation or alkylation at the alpha carbon of the amide bond linking two amino acids;
replacement of one or more alpha carbons with nitrogen atoms; and
binding of the amino group of one or more amino acid to the β carbon rather than the α carbon.
2. The pharmaceutical composition according to claim 1 , wherein said peptide is attached to a solid support.
3. The pharmaceutical composition according to claim 2 , wherein said solid support is an intravascular prosthesis.
4. The pharmaceutical composition according to claim 3 , wherein said intravascular prosthesis is a stent.
5. A medical device comprising an isolated peptide immobilized on a surface, wherein said peptide consists of:
(SEQ ID NO: 5)
(i)
H-RVFLAPWK-OH,
(SEQ ID NO: 6)
(ii)
H-kwpalfvr-OH,
(SEQ ID NO: 7)
(iii)
H-RVILAPWK-OH,
(SEQ ID NO: 8)
(iv)
H-kwpalivr-OH,
or
(v) a chemically modified peptide of (i), (ii), (iii), or (iv) which has at least one chemical modification selected from the group consisting of:
modification to the N-terminal and/or C-terminal end of the peptide by N-terminal acylation or deamination;
modification of the C-terminal carboxyl group into an amide or an alcohol group;
modification at the amide bond between two amino acids by acylation or alkylation at the nitrogen atom or the alpha carbon of the amide bond linking two amino acids;
modification at the alpha carbon of the amide bond linking two amino acids by acylation or alkylation at the alpha carbon of the amide bond linking two amino acids;
replacement of one or more alpha carbons with nitrogen atoms; and
binding of the amino group of one or more amino acid to the β carbon rather than the α carbon.
6. The medical device according to claim 5 , where said medical device is an intravascular prosthesis.
7. The medical device according to claim 6 , wherein said intravascular prosthesis is a stent.
8. A method for activating CD31-mediated signaling in vivo in an individual in need thereof, wherein said method comprises a step of administering to said individual a peptide consisting of:
(SEQ ID NO: 5)
(i)
H-RVFLAPWK-OH,
(SEQ ID NO: 6)
(ii)
H-kwpalfvr-OH,
(SEQ ID NO: 7)
(iii)
H-RVILAPWK-OH,
(SEQ ID NO: 8)
(iv)
H-kwpalivr-OH,
or
(v) a chemically modified peptide of (i), (ii), (iii), or (iv) which has at least one chemical modification selected from the group consisting of:
modification to the N-terminal and/or C-terminal end of the peptide by N-terminal acylation or deamination;
modification of the C-terminal carboxyl group into an amide or an alcohol group;
modification at the amide bond between two amino acids by acylation or alkylation at the nitrogen atom or the alpha carbon of the amide bond linking two amino acids;
modification at the alpha carbon of the amide bond linking two amino acids by acylation or alkylation at the alpha carbon of the amide bond linking two amino acids;
replacement of one or more alpha carbons with nitrogen atoms; and
binding of the amino group of one or more amino acid to the β carbon rather than the α carbon.
9. The method according to claim 8 , wherein said peptide is attached to a solid support.
10. The method according to claim 8 , wherein the peptide is administered subcutaneously.
11. The method according to claim 9 , wherein said solid support is an intravascular prosthesis.
12. A method for the treatment of atherosclerosis or multiple sclerosis in an individual in need thereof, wherein said method comprises a step of administering to said individual a peptide consisting of:
(SEQ ID NO: 5)
(i)
H-RVFLAPWK-OH,
(SEQ ID NO: 6)
(ii)
H-kwpalfvr-OH,
(SEQ ID NO: 7)
(iii)
H-RVILAPWK-OH,
(SEQ ID NO: 8)
(iv)
H-kwpalivr-OH,
or
(v) a chemically modified peptide of (i), (ii), (iii), or (iv) which has at least one chemical modification selected from the group consisting of:
modification to the N-terminal and/or C-terminal end of the peptide by N-terminal acylation or deamination;
modification of the C-terminal carboxyl group into an amide or an alcohol group;
modification at the amide bond between two amino acids by acylation or alkylation at the nitrogen atom or the alpha carbon of the amide bond linking two amino acids;
modification at the alpha carbon of the amide bond linking two amino acids by acylation or alkylation at the alpha carbon of the amide bond linking two amino acids;
replacement of one or more alpha carbons with nitrogen atoms; and
binding of the amino group of one or more amino acid to the β carbon rather than the α carbon.
13. The method according to claim 12 , wherein the peptide is attached to a solid support.
14. The method according to claim 13 , wherein said solid support is an intravascular prosthesis.
15. The method according to claim 12 , wherein the peptide is administered subcutaneously.